Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

EpiCept's AmiKet Receives FDA's Fast Track Designation

EpiCept Corp. (EPCT.PK) on Tuesday said its late-stage topical analgesic cream AmiKet has been granted fast track designation by the U.S. Food and Drug Administration.

The product is to treat neuropathic pain associated with chemotherapy-induced peripheral neuropathy, or CIPN, in patients previously treated with taxane-based chemotherapy.

The FDA's fast track program is designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and address unmet medical needs.

Products with such a designation often receive priority review, which may reduce the standard review time by half. The designation also allows for more frequent interactions with the FDA during the drug development process.

Jack Talley, President and Chief Executive Officer of EpiCept, said, "We believe the FDA Fast Track designation is confirmation of the pressing need for therapies to treat neuropathic pain associated with CIPN."

EpiCept had previously announced the engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet. The engagement will focus on the identification and implementation of a strategy to optimize AmiKet's value for the company's stockholders.

Register
To receive FREE breaking news email alerts for EpiCept Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.